ECSP19083621A - Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Info

Publication number
ECSP19083621A
ECSP19083621A ECSENADI201983621A ECDI201983621A ECSP19083621A EC SP19083621 A ECSP19083621 A EC SP19083621A EC SENADI201983621 A ECSENADI201983621 A EC SENADI201983621A EC DI201983621 A ECDI201983621 A EC DI201983621A EC SP19083621 A ECSP19083621 A EC SP19083621A
Authority
EC
Ecuador
Prior art keywords
dengue viral
inhibitors
compounds
indoline derivatives
viral replication
Prior art date
Application number
ECSENADI201983621A
Other languages
English (en)
Inventor
Arnaud Didier M Marchand
Bart Rudolf Romanie Kesteleyn
Boeck Benoit Christian Albert Ghislain De
Erwin Coesemans
Dorothée Alice Marie-Eve Bardiot
Jean-Francois Bonfanti
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Univ Leuven Kath
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Janssen Pharmaceuticals Inc filed Critical Univ Leuven Kath
Publication of ECSP19083621A publication Critical patent/ECSP19083621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a derivados de indolina sustituidos, a métodos para prevenir o tratar infecciones virales por dengue mediante el uso de dichos compuestos y también se refiere a dichos compuestos para su uso como medicamento, más preferentemente, para su uso como medicamento para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
ECSENADI201983621A 2017-05-22 2019-11-22 Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue ECSP19083621A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17172247 2017-05-22

Publications (1)

Publication Number Publication Date
ECSP19083621A true ECSP19083621A (es) 2019-11-30

Family

ID=58745159

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201983621A ECSP19083621A (es) 2017-05-22 2019-11-22 Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Country Status (29)

Country Link
US (2) US11053196B2 (es)
EP (1) EP3630724B1 (es)
JP (1) JP7179773B2 (es)
KR (1) KR102625991B1 (es)
CN (1) CN110753682B (es)
AR (1) AR111820A1 (es)
AU (1) AU2018274101C1 (es)
BR (1) BR112019024311A2 (es)
CA (1) CA3061026C (es)
CL (1) CL2019003309A1 (es)
CO (1) CO2019013042A2 (es)
CR (1) CR20190531A (es)
DK (1) DK3630724T3 (es)
EA (1) EA039702B1 (es)
EC (1) ECSP19083621A (es)
ES (1) ES2884157T3 (es)
HR (1) HRP20210724T1 (es)
HU (1) HUE054379T2 (es)
IL (1) IL270727B2 (es)
LT (1) LT3630724T (es)
MX (1) MX388870B (es)
PE (1) PE20200342A1 (es)
PH (1) PH12019502577A1 (es)
SI (1) SI3630724T1 (es)
TW (1) TWI771420B (es)
UA (1) UA125970C2 (es)
UY (1) UY37741A (es)
WO (1) WO2018215316A1 (es)
ZA (1) ZA201907713B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX393586B (es) 2017-05-22 2025-03-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EP4169925B1 (en) * 2018-06-19 2025-11-19 Novartis AG Process to make n-substituted tetrahydrothienopyridine derivatives
KR20250093588A (ko) 2018-12-27 2025-06-24 르 라보레또레 쎄르비에르 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
US20240368153A1 (en) 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US6861504B2 (en) 2001-05-03 2005-03-01 Cbr, Inc. Compounds and methods for the modulation of CD154
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2006204917A1 (en) 2005-01-14 2006-07-20 Smithkline Beecham Corporation Indole derivatives for treating viral infections
EA200701669A1 (ru) 2005-02-09 2008-02-28 Мидженикс Инк. Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
AP2010005480A0 (en) 2008-06-03 2010-12-31 Siga Technologies Inc Small molecule inhibitors for the treatment or prevention of denque virus infection.
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
EP2315303B1 (en) 2008-08-22 2012-11-28 Nippon Kayaku Kabushiki Kaisha Dye-sensitized photovoltaic device
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
JP2013523657A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのインダゾリル‐ピリミジン
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
EP3201176B1 (en) 2014-10-01 2018-12-12 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PL3201177T3 (pl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
NO2721243T3 (es) 2014-10-01 2018-10-20
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
UA123276C2 (uk) 2016-04-01 2021-03-10 Кайт Фарма, Інк. Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX393586B (es) 2017-05-22 2025-03-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Also Published As

Publication number Publication date
HUE054379T2 (hu) 2021-09-28
PH12019502577A1 (en) 2020-07-20
ES2884157T3 (es) 2021-12-10
SI3630724T1 (sl) 2021-08-31
TWI771420B (zh) 2022-07-21
EA201992784A1 (ru) 2020-04-23
DK3630724T3 (da) 2021-07-26
WO2018215316A1 (en) 2018-11-29
IL270727A (en) 2020-01-30
BR112019024311A2 (pt) 2020-07-28
US11702387B2 (en) 2023-07-18
LT3630724T (lt) 2021-08-25
CN110753682B (zh) 2023-06-30
EP3630724A1 (en) 2020-04-08
AR111820A1 (es) 2019-08-21
AU2018274101B2 (en) 2022-04-21
AU2018274101A1 (en) 2019-11-07
CR20190531A (es) 2020-03-05
CA3061026A1 (en) 2018-11-29
JP2020520950A (ja) 2020-07-16
UY37741A (es) 2018-11-30
AU2018274101C1 (en) 2022-09-15
HRP20210724T1 (hr) 2021-10-15
UA125970C2 (uk) 2022-07-20
ZA201907713B (en) 2022-03-30
KR20200010355A (ko) 2020-01-30
MX2019013878A (es) 2020-01-20
IL270727B (en) 2022-11-01
JP7179773B2 (ja) 2022-11-29
KR102625991B1 (ko) 2024-01-16
US20200181083A1 (en) 2020-06-11
US11053196B2 (en) 2021-07-06
CO2019013042A2 (es) 2020-01-17
TW201900611A (zh) 2019-01-01
CL2019003309A1 (es) 2020-03-20
CA3061026C (en) 2024-01-30
US20210300868A1 (en) 2021-09-30
EA039702B1 (ru) 2022-03-01
PE20200342A1 (es) 2020-02-14
EP3630724B1 (en) 2021-04-28
CN110753682A (zh) 2020-02-04
IL270727B2 (en) 2023-03-01
MX388870B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
MX2018003256A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicacion viral del dengue.
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue